Exatecan

未知生产厂商

Exatecan has been used in trials studying the treatment of Sarcoma, Leukemia, Lymphoma, Lung Cancer, and Liver Cancer, among others.

生成 AI 研报

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

Exatecan has been used in trials studying the treatment of Sarcoma, Leukemia, Lymphoma, Lung Cancer, and Liver Cancer, among others.

技术标识符

化学式: C₂₄H₂₂FN₃O₄
CAS 编号: 171335-80-1
UNII ID: OC71PP0F89

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES THEREOF
EP 4211145 B1申请人: GENEQUANTUM HEALTHCARE SUZHOU CO LTD优先权: 2021
CN
EP
US
WO
11 件公开
ANTI-MUC1- EXATECAN ANTIBODY-DRUG CONJUGATE
EP 3794042 B1申请人: DAIICHI SANKYO CO LTD优先权: 2018
CN
EP
US
WO
7 件公开
Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof
US 12617867 B2申请人: JIANGSU HENGRUI MEDICINE CO优先权: 2018
CN
EP
US
WO
7 件公开
Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload
- US 12419964 B2
  申请人: LILLY CO ELI优先权: 2023
  EP
  US
  WO
  6 件公开
- EP 4534102 A1
  申请人: LILLY CO ELI优先权: 2023
  EP
ANTI-B7H3 ANTIBODY-EXATECAN ANALOG CONJUGATE AND MEDICINAL USE THEREOF
EP 3854816 A4申请人: JIANGSU HENGRUI MEDICINE CO优先权: 2018
CN
EP
US
WO
5 件公开
ANTI-CEA ANTIBODY-EXATECAN ANALOG CONJUGATE AND PHARMACEUTICAL USE THEREOF
US 2023055408 A1申请人: JIANGSU HENGRUI MEDICINE CO优先权: 2019
CN
EP
US
WO
5 件公开
Anti-CD79B antibody-drug conjugate, and preparation method therefor and pharmaceutical use thereof
US 12642862 B2申请人: TUOJIE BIOTECH SHANGHAI CO LTD优先权: 2020
EP
US
WO
5 件公开
ANTI-CEACAM5 ANTIBODY DRUG CONJUGATES
EP 4658320 A1申请人: BRISTOL MYERS SQUIBB CO优先权: 2024
EP
US
WO
5 件公开
ANTI-TROP-2 ANTIDODY-EXATECAN ANALOG CONJUGATE AND MEDICAL USE THEREOF
EP 4095148 A4申请人: JIANGSU HENGRUI MEDICINE CO优先权: 2020
CN
EP
US
WO
4 件公开
ANTI-PSMA ANTIBODY-EXATECAN ANALOGUE CONJUGATE AND MEDICAL USE THEREOF
EP 4130006 A4申请人: JIANGSU HENGRUI PHARMACEUTICALS CO LTD优先权: 2020
CN
EP
US
WO
4 件公开

药物

Exatecan

概览

专利

Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload